亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial

医学 中期分析 内科学 临床终点 危险系数 肿瘤科 化疗 新辅助治疗 围手术期 食管癌 不利影响 随机对照试验 癌症 外科 置信区间 乳腺癌
作者
Yan Zheng,Guanghui Liang,Dongfeng Yuan,Xianben Liu,Yufeng Ba,Zimin Qin,Sining Shen,Zhenxuan Li,Haibo Sun,Baoxing Liu,Quanli Gao,Peng Li,Zongfei Wang,Shilei Liu,Jianping Zhu,Haoran Wang,Haibo Ma,Zhenzhen Liu,Fei Zhao,Jun Zhang
出处
期刊:Cancer communications [Wiley]
被引量:7
标识
DOI:10.1002/cac2.12604
摘要

Abstract Background In the era of immunotherapy, neoadjuvant immunochemotherapy (NAIC) for the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) is used clinically but lacks of high‐level clinical evidence. This study aimed to compare the safety and long‐term efficacy of NAIC followed by minimally invasive esophagectomy (MIE) with those of neoadjuvant chemotherapy (NAC) followed by MIE. Methods A prospective, single‐center, open‐label, randomized phase III clinical trial was conducted at Henan Cancer Hospital, Zhengzhou, China. Patients were randomly assigned to receive either neoadjuvant toripalimab (240 mg) plus paclitaxel (175 mg/m 2 ) + cisplatin (75 mg/m 2 ) (toripalimab group) or paclitaxel + cisplatin alone (chemotherapy group) every 3 weeks for 2 cycles. After surgery, the toripalimab group received toripalimab (240 mg every 3 weeks for up to 6 months). The primary endpoint was event‐free survival (EFS). The pathological complete response (pCR) and overall survival (OS) were key secondary endpoints. Adverse events (AEs) and quality of life were also assessed. Results Between May 15, 2020 and August 13, 2021, 252 ESCC patients ranging from T1N1‐3M0 to T2‐3N0‐3M0 were enrolled for interim analysis, with 127 in the toripalimab group and 125 in the chemotherapy group. The 1‐year EFS rate was 77.9% in the toripalimab group compared to 64.3% in the chemotherapy group (hazard ratio [HR] = 0.62; 95% confidence interval [CI] = 0.39 to 1.00; P = 0.05). The 1‐year OS rates were 94.1% and 83.0% in the toripalimab and chemotherapy groups, respectively (HR = 0.48; 95% CI = 0.24 to 0.97; P = 0.037). The patients in the toripalimab group had a higher pCR rate (18.6% vs. 4.6%; P = 0.001). The rates of postoperative Clavien‐Dindo grade IIIb or higher morbidity were 9.8% in the toripalimab group and 6.8% in the chemotherapy group, with no significant difference observed ( P = 0.460). The rates of grade 3 or 4 treatment‐related AEs did not differ between the two groups (12.5% versus 12.4%). Conclusions The interim results of this ongoing trial showed that in resectable ESCC, the addition of perioperative toripalimab to NAC is safe, may improve OS and might change the standard treatment in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2311完成签到 ,获得积分20
3秒前
2311关注了科研通微信公众号
6秒前
14秒前
19秒前
kento完成签到,获得积分0
21秒前
fang完成签到,获得积分10
25秒前
Tumumu完成签到,获得积分10
25秒前
Li完成签到,获得积分10
30秒前
fang发布了新的文献求助10
31秒前
科目三应助科研通管家采纳,获得10
33秒前
orixero应助科研通管家采纳,获得10
33秒前
科研通AI2S应助科研通管家采纳,获得10
33秒前
共享精神应助科研通管家采纳,获得10
33秒前
科目三应助科研通管家采纳,获得10
33秒前
Jasper应助科研通管家采纳,获得10
33秒前
33秒前
英俊的铭应助lf采纳,获得10
34秒前
43秒前
lf发布了新的文献求助10
46秒前
量子星尘发布了新的文献求助10
48秒前
Alice应助Magali采纳,获得80
56秒前
57秒前
乐乱完成签到 ,获得积分10
1分钟前
背后梦安发布了新的文献求助30
1分钟前
1分钟前
1分钟前
乂贰ZERO叁完成签到 ,获得积分10
1分钟前
1分钟前
xiaoya完成签到,获得积分10
1分钟前
Ultraman45发布了新的文献求助10
1分钟前
F_echo完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
bbdd2334发布了新的文献求助10
1分钟前
科目三应助lf采纳,获得10
2分钟前
2分钟前
科研通AI5应助瘦瘦的寒珊采纳,获得10
2分钟前
lf发布了新的文献求助10
2分钟前
NanNan626完成签到,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976643
求助须知:如何正确求助?哪些是违规求助? 3520735
关于积分的说明 11204613
捐赠科研通 3257484
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613